Developer docs
API playgroundTry for free, no card

Search company profiles

Marvel Biosciences

Full company profile

uuid0002d4m

Namestring
Marvel Biosciences
Legal namestring
Marvel Biosciences Corp.
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Marvel Biosciences Corp. is a Calgary, Alberta-based clinical-stage pharmaceutical biotechnology company developing synthetic derivatives of known drugs for neurodevelopmental and neurodegenerative disorders. The company's lead asset, MB-204, is a novel fluorinated analogue of Istradefylline — an adenosine A2A receptor antagonist originally approved for Parkinson's disease — being repositioned as a first-in-class treatment targeting social reward pathways for neuropsychiatric conditions including autism spectrum disorder, Rett syndrome, Fragile X syndrome, depression, and Alzheimer's disease. Preclinically, MB-204 significantly outperformed the approved Rett syndrome therapy trofinetide across multiple efficacy endpoints and has been formulated into two pediatric-friendly liquid dosage forms achieving 79% and 91% oral bioavailability in mouse studies, addressing a key unmet need for children with swallowing difficulties or feeding-tube dependence. The company has secured composition-of-matter patents in the United States, Japan, China, and Australia (allowed).

Marvel operates as a pre-revenue, publicly listed entity on the TSX Venture Exchange through its wholly-owned operating subsidiary Marvel Biotechnology Inc. Its go-to-market model is licensing- and partnership-driven: future revenue is expected through pharmaceutical out-licensing deals, co-development arrangements, or eventual commercialization following regulatory approval, with no current pricing or commercial products. The company is conducting its Phase I clinical trial in Australia through CRO partner Novotech, leveraging the country's R&D tax credits exceeding 40% of trial costs, and has assembled a lean capital stack combining non-dilutive grants (Alberta Innovates AICE, NRC IRAP), strategic investment (5 Horizon Ventures covering 15% of trial costs), private placements (approximately CAD $1 million issued in April 2026 at $0.125 per unit), and a CAD $500,000 unsecured convertible debenture (12% interest, maturing December 31, 2027). The company engages in business development through industry conferences and partnering summits, with Chief Science Officer Dr. Mark Williams presenting MB-204 at the 2nd Neuroscience Innovation Partnering & Licensing Summit in Boston in April 2026.

Short descriptiontext

Marvel Biosciences is a Calgary-based clinical-stage biotech developing MB-204, a novel fluorinated adenosine A2A receptor antagonist for autism, Rett syndrome, Fragile X, depression, and Alzheimer's. Pre-revenue, with future revenue expected from pharmaceutical licensing deals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCalgary, Canada
HQ citystring
Calgary
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
adenosine receptor antagonists, neurodevelopmental therapeutics, clinical-stage biotechnology, central nervous system drugs, pediatric drug formulations
Industry3 codes
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Neurodevelopmental Therapeutics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Licensing
TypeLicensing Royalties
Description

Pre-revenue clinical stage biotech company. Future revenue expected through pharmaceutical licensing deals, co-development partnerships, or eventual product commercialization following successful clinical trials and regulatory approval.

biospace.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Marvel Biosciences is developing MB-204, a novel fluorinated derivative of the FDA-approved Parkinson's drug Istradefylline, which acts as an adenosine A2A receptor antagonist. MB-204 is being advanced as a first-in-class treatment targeting social reward pathways for neurodevelopmental and neurodegenerative disorders including autism spectrum disorder, Rett syndrome, Fragile X syndrome, depression, and Alzheimer's disease, with pediatric-friendly oral liquid formulations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • MB-204 significantly outperformed the approved therapy trofinetide across multiple efficacy endpoints in Rett syndrome preclinical models
+1 more record
Product overview1 text field

Marvel Biosciences is a Calgary-based preclinical-stage pharmaceutical biotechnology company focused on discovering and developing synthetic derivatives of known drugs for neurological and neurodevelopmental disorders. The company's primary product is MB-204, a novel fluorinated derivative of the FDA-approved anti-Parkinson's drug Istradefylline, which acts as a neuroactive adenosine A2A receptor antagonist. MB-204 is being developed as a potential first-in-class treatment for conditions including autism spectrum disorder, Rett syndrome, Fragile X syndrome, depression, and Alzheimer's disease. The company is advancing MB-204 through preclinical toxicology studies toward Phase I clinical trials, with multiple composition-of-matter patents granted across major jurisdictions including the US, Japan, China, and Australia.

Product and service1 record
1MB-204
CategoryLead Pharmaceutical Compound
Description

MB-204 is a novel fluorinated derivative of Istradefylline (an adenosine A2A receptor antagonist) being developed as a first-in-class treatment targeting social reward pathways for neuropsychiatric disorders including autism spectrum disorder, Rett syndrome, Fragile X syndrome, depression, and Alzheimer's disease. In preclinical Rett syndrome models it significantly outperformed the approved therapy trofinetide across multiple efficacy endpoints. Pediatric-friendly oral liquid formulations achieving 79–91% oral bioavailability have been identified.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Marvel Biosciences selected Novotech as their contract research organization (CRO) to conduct the Phase I clinical trial of MB-204 in Australia. The trial will leverage Australia's favorable regulatory environment and tax credits exceeding 40% of costs, marking MB-204's transition into human trials.

23rd European Purine Meeting
Strategic tierMinorTypeOthers
Description

Marvel Biosciences sponsors the 3rd European Purine Meeting in Bordeaux, France (June 30 - July 3, 2026). The event focuses on sharing new discoveries in purinergic system research, which is involved in diseases such as Alzheimer's and autism, with potential implications for future therapies.

stocktitan.net
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing ANAVEX 2-73 (blarcamesine) for Rett syndrome, Fragile X, and Alzheimer's - directly overlapping MB-204's indications and targeting rare pediatric neurodevelopmental populations.

TypeDirect peer
Description

Acadia markets Daybue (trofinetide), the only FDA-approved therapy for Rett syndrome - the same indication where MB-204 demonstrated preclinical outperformance. Both companies target rare pediatric neurodevelopmental disorders with CNS-active molecules.

TypeDirect peer
Description

Kyowa Kirin markets Nourianz (istradefylline), the FDA-approved A2A receptor antagonist from which Marvel's MB-204 is derived. Direct mechanistic and structural precedent for MB-204's A2A pharmacology.

TypeDirect peer
Description

European CNS-focused biotech that developed/develops therapies for Rett syndrome and other neurodevelopmental disorders, including partnerships with major pharma for CNS assets.

TypeDirect peer
Description

Developed Ztalmy (ganaxolone) for CDKL5 deficiency disorder and other rare pediatric neurological epilepsies. Operates in the same rare pediatric neurodevelopment niche with FDA-approved CNS assets.

TypeBroad incumbent
Description

Commercial CNS specialty pharma with approved products in depression and migraine. Comparable specialty neurology/neuropsychiatry commercialization model for MB-204's depression and broader CNS indications.

TypeBroad incumbent
Description

CNS-focused commercial pharma (Caplyta for schizophrenia/depression) with parallel development model in neuropsychiatric indications where MB-204 is also being positioned.

TypeBroad incumbent
Description

CNS therapeutics company (Zurzuvae for postpartum depression) with a development and commercialization footprint in the same neurology/psychiatry category where MB-204 is targeting depression and ASD.

TypeBroad incumbent
Description

Established rare disease biotech with multiple approved rare pediatric therapies. Represents the typical strategic acquirer/licensor profile for a rare pediatric neurodevelopment asset like MB-204.

TypeEmerging player
Description

Clinical-stage neuroscience company developing therapies for CNS disorders including Parkinson's and psychiatry - overlapping with MB-204's A2A mechanism and broader neurology positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Marvel Biosciences

Neurodevelopmental Therapeuticsmarvelbiotechnology.com

Marvel Biosciences is a Calgary-based clinical-stage biotech developing MB-204, a novel fluorinated adenosine A2A receptor antagonist for autism, Rett syndrome, Fragile X, depression, and Alzheimer's. Pre-revenue, with future revenue expected from pharmaceutical licensing deals.

What Marvel Biosciences does

Marvel Biosciences Corp. is a Calgary, Alberta-based clinical-stage pharmaceutical biotechnology company developing synthetic derivatives of known drugs for neurodevelopmental and neurodegenerative disorders. The company's lead asset, MB-204, is a novel fluorinated analogue of Istradefylline — an adenosine A2A receptor antagonist originally approved for Parkinson's disease — being repositioned as a first-in-class treatment targeting social reward pathways for neuropsychiatric conditions including autism spectrum disorder, Rett syndrome, Fragile X syndrome, depression, and Alzheimer's disease. Preclinically, MB-204 significantly outperformed the approved Rett syndrome therapy trofinetide across multiple efficacy endpoints and has been formulated into two pediatric-friendly liquid dosage forms achieving 79% and 91% oral bioavailability in mouse studies, addressing a key unmet need for children with swallowing difficulties or feeding-tube dependence. The company has secured composition-of-matter patents in the United States, Japan, China, and Australia (allowed).

Marvel operates as a pre-revenue, publicly listed entity on the TSX Venture Exchange through its wholly-owned operating subsidiary Marvel Biotechnology Inc. Its go-to-market model is licensing- and partnership-driven: future revenue is expected through pharmaceutical out-licensing deals, co-development arrangements, or eventual commercialization following regulatory approval, with no current pricing or commercial products. The company is conducting its Phase I clinical trial in Australia through CRO partner Novotech, leveraging the country's R&D tax credits exceeding 40% of trial costs, and has assembled a lean capital stack combining non-dilutive grants (Alberta Innovates AICE, NRC IRAP), strategic investment (5 Horizon Ventures covering 15% of trial costs), private placements (approximately CAD $1 million issued in April 2026 at $0.125 per unit), and a CAD $500,000 unsecured convertible debenture (12% interest, maturing December 31, 2027). The company engages in business development through industry conferences and partnering summits, with Chief Science Officer Dr. Mark Williams presenting MB-204 at the 2nd Neuroscience Innovation Partnering & Licensing Summit in Boston in April 2026.

Marvel Biosciences firmographics

Firmographics
Name
Marvel Biosciences
Legal name
Marvel Biosciences Corp.
Website
https://marvelbiotechnology.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Marvel Biosciences is a Calgary-based clinical-stage biotech developing MB-204, a novel fluorinated adenosine A2A receptor antagonist for autism, Rett syndrome, Fragile X, depression, and Alzheimer's. Pre-revenue, with future revenue expected from pharmaceutical licensing deals.
Ownership category
akta.pro rank

Marvel Biosciences industry classification

Industry
Product category
Neurodevelopmental Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Adenosine receptor antagonists
  • Neurodevelopmental therapeutics
  • Clinical-stage biotechnology
  • Central nervous system drugs
  • Pediatric drug formulations

Where Marvel Biosciences is headquartered

Location

Headquarters

HQ city
Calgary
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Marvel Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

  1. Drug Development and Licensing: Pre-revenue clinical stage biotech company. Future revenue expected through pharmaceutical licensing deals, co-development partnerships, or eventual product commercialization following successful clinical trials and regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Marvel Biosciences product offering

Product offering

Core offering

Marvel Biosciences is developing MB-204, a novel fluorinated derivative of the FDA-approved Parkinson's drug Istradefylline, which acts as an adenosine A2A receptor antagonist. MB-204 is being advanced as a first-in-class treatment targeting social reward pathways for neurodevelopmental and neurodegenerative disorders including autism spectrum disorder, Rett syndrome, Fragile X syndrome, depression, and Alzheimer's disease, with pediatric-friendly oral liquid formulations.

Product overview

Marvel Biosciences is a Calgary-based preclinical-stage pharmaceutical biotechnology company focused on discovering and developing synthetic derivatives of known drugs for neurological and neurodevelopmental disorders. The company's primary product is MB-204, a novel fluorinated derivative of the FDA-approved anti-Parkinson's drug Istradefylline, which acts as a neuroactive adenosine A2A receptor antagonist. MB-204 is being developed as a potential first-in-class treatment for conditions including autism spectrum disorder, Rett syndrome, Fragile X syndrome, depression, and Alzheimer's disease. The company is advancing MB-204 through preclinical toxicology studies toward Phase I clinical trials, with multiple composition-of-matter patents granted across major jurisdictions including the US, Japan, China, and Australia.

Differentiator

Problem solved

Functional benefit

Products and services

  • MB-204 MB-204 is a novel fluorinated derivative of Istradefylline (an adenosine A2A receptor antagonist) being developed as a first-in-class treatment targeting social reward pathways for neuropsychiatric disorders including autism spectrum disorder, Rett syndrome, Fragile X syndrome, depression, and Alzheimer's disease. In preclinical Rett syndrome models it significantly outperformed the approved therapy trofinetide across multiple efficacy endpoints. Pediatric-friendly oral liquid formulations achieving 79–91% oral bioavailability have been identified.

Quantifiable outcome

  • MB-204 significantly outperformed the approved therapy trofinetide across multiple efficacy endpoints in Rett syndrome preclinical models
  • +1 more outcomes

Companies that use Marvel Biosciences

Customer profile

Segments6 records

Ideal customer profiles1 record

Marvel Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Marvel Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • NovotechcoreImplementation/ SI/ Consulting PartnerMarvel Biosciences selected Novotech as their contract research organization (CRO) to conduct the Phase I clinical trial of MB-204 in Australia. The trial will leverage Australia's favorable regulatory environment and tax credits exceeding 40% of costs, marking MB-204's transition into human trials.
  • 3rd European Purine MeetingminorOthersMarvel Biosciences sponsors the 3rd European Purine Meeting in Bordeaux, France (June 30 - July 3, 2026). The event focuses on sharing new discoveries in purinergic system research, which is involved in diseases such as Alzheimer's and autism, with potential implications for future therapies.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Marvel Biosciences competitors and assessment

Company assessment

Direct peers

  • Anavex Life Sciences: Clinical-stage biotech developing ANAVEX 2-73 (blarcamesine) for Rett syndrome, Fragile X, and Alzheimer's - directly overlapping MB-204's indications and targeting rare pediatric neurodevelopmental populations.
  • Acadia Pharmaceuticals: Acadia markets Daybue (trofinetide), the only FDA-approved therapy for Rett syndrome - the same indication where MB-204 demonstrated preclinical outperformance. Both companies target rare pediatric neurodevelopmental disorders with CNS-active molecules.
  • Kyowa Kirin: Kyowa Kirin markets Nourianz (istradefylline), the FDA-approved A2A receptor antagonist from which Marvel's MB-204 is derived. Direct mechanistic and structural precedent for MB-204's A2A pharmacology.
  • Newron Pharmaceuticals: European CNS-focused biotech that developed/develops therapies for Rett syndrome and other neurodevelopmental disorders, including partnerships with major pharma for CNS assets.
  • Marinus Pharmaceuticals: Developed Ztalmy (ganaxolone) for CDKL5 deficiency disorder and other rare pediatric neurological epilepsies. Operates in the same rare pediatric neurodevelopment niche with FDA-approved CNS assets.

Broad incumbents

  • Axsome Therapeutics: Commercial CNS specialty pharma with approved products in depression and migraine. Comparable specialty neurology/neuropsychiatry commercialization model for MB-204's depression and broader CNS indications.
  • Intra-Cellular Therapies: CNS-focused commercial pharma (Caplyta for schizophrenia/depression) with parallel development model in neuropsychiatric indications where MB-204 is also being positioned.
  • Sage Therapeutics: CNS therapeutics company (Zurzuvae for postpartum depression) with a development and commercialization footprint in the same neurology/psychiatry category where MB-204 is targeting depression and ASD.
  • BioMarin Pharmaceutical: Established rare disease biotech with multiple approved rare pediatric therapies. Represents the typical strategic acquirer/licensor profile for a rare pediatric neurodevelopment asset like MB-204.

Emerging players

  • Cerevel Therapeutics: Clinical-stage neuroscience company developing therapies for CNS disorders including Parkinson's and psychiatry - overlapping with MB-204's A2A mechanism and broader neurology positioning.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Marvel Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Marvel Biosciences leadership team

Management profile

Number of profiles

Profiles1 record

Marvel Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Marvel Biosciences funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Marvel Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marvel Biosciences

What does Marvel Biosciences do?

Marvel Biosciences is developing MB-204, a novel fluorinated derivative of the FDA-approved Parkinson's drug Istradefylline, which acts as an adenosine A2A receptor antagonist. MB-204 is being advanced as a first-in-class treatment targeting social reward pathways for neurodevelopmental and neurodegenerative disorders including autism spectrum disorder, Rett syndrome, Fragile X syndrome, depression, and Alzheimer's disease, with pediatric-friendly oral liquid formulations.

Is Marvel Biosciences a public or private company?

Marvel Biosciences is a public company. It is classified as public and is currently operating.

When was Marvel Biosciences founded?

Marvel Biosciences was founded in 2018. It employs 1 to 10 people.

Where is Marvel Biosciences based?

Marvel Biosciences is headquartered in Calgary, Canada, in the North America region.

How does Marvel Biosciences make money?

One revenue line is on record: drug Development and Licensing.

Who are Marvel Biosciences's main competitors?

Direct peers on record are Anavex Life Sciences, Acadia Pharmaceuticals, Kyowa Kirin, Newron Pharmaceuticals and Marinus Pharmaceuticals. Broad incumbents are Axsome Therapeutics, Intra-Cellular Therapies, Sage Therapeutics and BioMarin Pharmaceutical. Cerevel Therapeutics is listed as an emerging player.

Does Marvel Biosciences have an API?

No public API is recorded for Marvel Biosciences.

What industry is Marvel Biosciences in?

Marvel Biosciences's product category is Neurodevelopmental Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewMarvel Biosciences Corp. (MRVL) Awards Directors 59,693 Deferred Share UnitsMarvel Biosciences awarded 59,693 deferred share units to three independent directors in lieu of cash fees, valued at $0.13 per share. The units vest November 18, 2027, and the disclosure does not quantify cash savings.stockhouseMarvel Biosciences shares preliminary MB-204 autism mouse-study dataMarvel Biosciences released preliminary data from a mouse study of its autism drug candidate MB-204, which normalized six behavioral measures at high doses while istradefylline did not. The company also disclosed two paid investor-marketing engagements subject to TSX Venture Exchange acceptance. Marvel plans to test MB-204 in patients for its Phase 1 clinical trial.stockhouse2 micro-cap stocks on contrasting paths to long-term growthSono-Tek Corp. and Marvel Biosciences Corp. are profiled as micro-cap stocks with contrasting growth paths. Sono-Tek, a coating-systems provider, reported revenue growth from $14.8M to $20.9M and a $9.51M backlog. Marvel Biosciences, a biotech, is developing MB-204 for neurological disorders, with a phase-1 trial planned in Australia.AktienCEO.CA's Inside the Boardroom: No Approved Drug Does What Marvel's Lead Candidate Can Do for AutismMarvel Biosciences Corp. is entering human trials with its lead drug candidate MB204 for autism, which has no approved treatments. The company's novel therapy aims to deliver fast-acting, persistent relief by turning off brain circuits. The interview was recorded on October 13, 2026.Business & FinancialMarvel Biosciences Advances MB-204 Toward First-In Human Testing, Selects CMAX As Phase I Clinical Trial SiteMarvel Biosciences selected CMAX Clinical Research in Australia as the Phase I trial site for MB-204, a fluorinated Istradefylline derivative. The company plans a single ascending dose study to assess safety, tolerability, and pharmacokinetics, with initiation pending regulatory and ethics approvals.TradingViewMarvel Biosciences Corp. (MRVL) Selects CMAX for MB-204 Phase IMarvel Biosciences selected CMAX in Adelaide, Australia, as the site for its planned Phase I first-in-human study of MB-204. The study will assess safety, tolerability, and pharmacokinetics, with biomarkers and cognitive endpoints, subject to regulatory and ethics approvals. A MAD study is planned if initial safety supports progression.Financial PostMarvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate UpdateMarvel Biosciences signed a letter of intent with Novatech to conduct a Phase 1 trial of MB-204, a drug for autism spectrum disorder. The trial, planned in Australia, is expected to begin in Q4 2026 and will assess safety, tolerability, and pharmacokinetics. The company will update on single and multiple ascending dose studies as they progress.The future of tradingMarvel Biosciences closes private placement, raises $1,598,144.70 in gross proceedsMarvel Biosciences closed a non-brokered private placement, issuing 10,654,298 units at $0.15 for gross proceeds of $1,598,144.70. Each unit includes one common share and one warrant exercisable at $0.20, with expiry acceleration if the TSXV 5-day VWAP reaches $0.25. Net proceeds will fund a Phase 1 clinical-trial deposit for MB-204, general and administrative costs, and working capital.Seeking AlphaMarvel Biosciences announces non‑brokered private placement for up to $3M (MRVL:CA:TSXV)Marvel Biosciences announced a non-brokered private placement at $0.15 per unit, offering 10-20 million units for gross proceeds of $1.5-3 million. The offering is intended to raise capital for the company.AInvestMarvel Biosciences Completes $3M Private Placement OfferingMarvel Biosciences completed a non-brokered private placement of up to $3.0 million, issuing 20 million units at $0.15 each. Each unit includes a common share and a warrant exercisable at $0.20, with accelerated expiry if the stock reaches $0.25. Proceeds will fund phase 1 trials of MB-204, operational costs, and working capital.